Filing Flows › Amneal Pharmaceuticals (AMRX) › Q1 2025
Amneal Pharmaceuticals (AMRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Amneal Pharmaceuticals (AMRX) reported revenue of $695M for the first quarter 2025 (Q1 2025), +5% from a year earlier and -5% from the quarter before. Operating margin was 14.4%, net earnings $12.2M (1.8% of revenue).
Amneal Pharmaceuticals, Q1 2025: revenue $695M (+6% year over year), operating margin 14.4%, net earnings $12.2M, operating cash flow $7.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $695M | -5% | +5% |
| Gross profit | $256M | -3% | +7% |
| Operating profit | $100M | +32% | — |
| Net earnings | $12.2M | — | — |
| Operating cash flow | $7.4M | -94% | — |
What changed
Revenue was $695.4M in Q1 2025, up 5% year over year and down 5% from the previous quarter.
Gross margin was 36.8%, up 0.7 points from a year earlier. Operating profit was $100.3M, a 14.4% margin (up 16.1 points year over year). Operating expenses fell 37% while revenue rose 5%. Net earnings were $12.2M. The effective tax rate was 34.3%.
Operating cash flow was $7.4M, 30% of net income including minority interests. Non-cash charges added back $7.3M of share-based compensation. Working capital and other items used $24.5M. Capital expenditures of $13.2M exceeded it, leaving free cash flow of −$5.8M.
Questions
What was Amneal Pharmaceuticals' revenue in the first quarter 2025?
Amneal Pharmaceuticals (AMRX) reported revenue of $695M for the first quarter 2025 (Q1 2025), +5% from a year earlier and -5% from the quarter before.
Was Amneal Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $100M (14.4% of revenue) and net earnings $12.2M.